Combined inhaled beta-agonist and anticholinergic agents for emergency management in adults with asthma

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 1, 2017, Pages

  Kirkland, Scott W ^a   Vandenberghe, Christine ^a   Voaklander, Britt ^a   Nikel, Taylor ^a   Campbell, Sandra ^a   Rowe, Brian H ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; ANTIASTHMATIC AGENT; ATROPINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; IPRATROPIUM BROMIDE; LEVALBUTEROL; ORCIPRENALINE; OXITROPIUM BROMIDE; SALBUTAMOL; SCOPOLAMINE DERIVATIVE;

ADULT; AGITATION; ASTHMA; BLURRED VISION; CINAHL; COMBINATION DRUG THERAPY; DISEASE EXACERBATION; DRUG EFFICACY; EMBASE; EMERGENCY TREATMENT; EMERGENCY WARD; FORCED EXPIRATORY VOLUME; HEADACHE; HEART PALPITATION; HOSPITALIZATION; HUMAN; LUNG FUNCTION; MEDLINE; META ANALYSIS; NAUSEA; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SCOPUS; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREMOR; XEROSTOMIA; DRUG EFFECTS;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; ANTI-ASTHMATIC AGENTS; ASTHMA; ATROPINE; CHOLINERGIC ANTAGONISTS; DRUG THERAPY, COMBINATION; FORCED EXPIRATORY VOLUME; HUMANS; IPRATROPIUM; LEVALBUTEROL; METAPROTERENOL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCOPOLAMINE DERIVATIVES;

EID: 85009291675     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD001284.pub2     Document Type: Review

References (91)

1. Aggarwal P, Singh O, Wali JP, Handa R, Dwivedi SN, Biswas A, et al. Efficacy of nebulised ipratropium in acute bronchial asthma. Journal, Indian Academy of Clinical Medicine 2002;3(4):353-9. [4488410]
2. Canete C, Esteban LL, Sanchon BR, Manresa F. Treatment with anticholinergics in the asthmatic crisis [Tratamiento con anticholinérgicos en la crisis asmática]. Archivos De Bronconeumologia 1991;27(Suppl 1):44. [4488412]
3. Cydulka RK, Emerman CL, Muni A. Levelbuterol versus lebalbuterol plus ipratropium in the treatment of severe acute asthma. Journal of Asthma 2010;47(10):1094-100. [4488414]
4. Diaz JE, Dubin R, Gaeta TJ, Pelczar P, Bradley K. Efficacy of atropine sulfate in combination with albuterol in the treatment for acute asthma. Academic Emergency Medicine 1997;4(2):107-13. [4488416]
5. FitzGerald JM, Grunfeld A, Pare PD, Levy RD, Newhouse MT, Hodder R, et al. The clinical efficacy of combination nebulized anticholinergic and adrenergic bronchodilators vs nebulized adrenergic bronchodilator alone in acute asthma. Canadian Combivent Study Group. Chest 1997;111(2):311-5. [4488418]
6. Garrett JE, Town GI, Rodwell P, Kelly AM. Nebulized salbutamol with and without ipratropium bromide in the treatment of acute asthma. Journal of Allergy and Clinical Immunology 1997;100(2):165-70. [4488420]
7. Hossain AS, Barua UK, Roy GC, Sutradhar SR, Rahman I, Rahman G. Comparison of salbutamol and ipratropium bromide versus salbutamol alone in the treatment of acute severe asthma. Mymensingh Medical Journal 2013;22(2):345-52. [4488422]
8. Kamei T, Fujita J, Okada H, Nakamura H, Kishimoto T, Momoi A, et al. Comparison between fenoterol and fenoterol plus oxitropium bromide delivered by metered-dose inhaler with inspirease to relieve acute asthma attack. Journal of Asthma 1999;36(1):67-75. [4488424]
9. Karpel JP, Schacter EN, Fanta C, Levey D, Spiro P, Aldrich T, et al. A comparison of ipratropium and albuterol vs. albuterol alone for the treatment of acute asthma. Chest 1996;110:611-6. [4488426]
10. Kohistani TA. Acute severe asthma; salbutamol plus ipratropium bromide nebulization versus salbutomol nebulization alone. Professional Medical Journal 2007;14(4):586-90. [4488428]
11. Lin RY, Pesola GR, Bakalchuk L, Morgan JP, Heyl GT, Freyberg CW, et al. Superiority of ipratropium plus albuterol over albuterol alone in the emergency department management of adult asthma: a randomized clinical trial. Annals of Emergency Medicine 1998;31(2):208-13. [4488430]
12. Nakano Y, Enomoto N, Kawamoto A, Hirai R, Chida K. Efficacy of adding multiple doses of oxitropium bromide to salbutomol delivered by means of a metered-dose inhaler with a spacer device in adults with acute severe asthma. Journal of Allergy and Clinical Immunology 2000;106(3):472-8. [4488432]
13. O'Driscoll BR, Taylor RJ, Horsley MG, Chambers DK, Bernstein A. Nebulised salbutomol with and without ipratropium bromide in acute airflow obstruction. Lancet 1989;333(8652):1418-20. [4488434]
14. Owens MW, George RB. Nebulized atropine sulfate in the treatment of acute asthma. Chest 1991;99(5):1084-7. [4488436]
15. Rahman SMS, Hossain AH, Hasan R, Mahmood AM. First-line therapy for adult patient with acute asthma receiving a multiple-dose regime of ipratropium bromide plus salbutamol in the emergency department. Indian Journal of Allergy Asthma and Immunology 2006;20(2):129. [4488438]
16. Rashid M, Khair M, Hossain A, Hassan R. A newer treatment regime for adult acute asthmatics with inhaled ipratropium bromide and salbutamol in multiple intermittent doses using a volumetric spacer in emergency setting. Respirology 2010;15(Suppl 2):56. [4488440]
17. Rebuck AS, Chapman KR, Abboud R, Pare PD, Kreisman H, Wolkove N, et al. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. American Journal of Medicine 1987;82:59-64. [4488442]
18. Rodrigo Gorina CP, Rodrigo Gorina GJ. Treatment or asthma with high doses of salbutamol and ipratropium bromide administered through metered dose inhaler and holding chamber [Tratamiento de la crisis asmática con altas dosis de salbutamol y brumuro de ipratropio administrados mediante inhalador de dosis medida e inhalocámara]. Paciente Critico 1995;8(3):175-84. [4488444]
19. Rodrigo GJ, Rodrigo C. First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department. American Journal of Respiratory and Critical Care Medicine 2000;161(6):1862-8. [4488446]
20. Salo D, Tuel M, Lavery RF, Reischel U, Lebowitz J, Moore T. A randomized, clinical trial comparing the efficacy of continuous nebulized albuterol (15 mg) versus continuous nebulized albuterol (15 mg) plus ipratropium bromide (2 mg) for the treatment of acute asthma. Journal of Emergency Medicine 2006;31(4):371-6. [4488448]
21. Solarte I, Sanchez LY, Lasso JI, Londono D. Ipratropium bromide plus salbutamol in the emergency management of acute asthma exacerbation (AAE). American Journal of Respiratory and Critical Care Medicine 2004;169(Suppl 7):A37. [4488450]
22. Summers QA, Tarala RA. Nebulized ipratropium in the treatment of acute asthma. Chest 1990;97(2):425-9. [4488452]
23. Weber EJ, Levitt MA, Covington JK, Gambrioli E. Effect of continuously nebulized ipratropium bromide plus albuterol on emergency department length of stay and hospital admission rates in patients with acute bronchospasm. A randomized, controlled trial. Chest 1999;115(4):937-44. [4488454]
24. Anonymous Terbutaline and ipratropium for nebulization. Prescire International 1994;3(11):71-4. [4488456]
25. Barrett MJ. Combined anti-cholinergic and short-acting beta-agonist therapy reduces hospital admissions for acute asthma. Journal of Paediatric Child Health 2014;50(7):577-8. [4488458]
26. Beck R, Robertson C, Galdes-Sebaldt M, Levison H. Combined salbutomol and ipratropium bromide by inhalation in the treatment of severe acute asthma. Journal of Pediatrics 1985;107(4):605-8. [4488460]
27. Bonsignore G, Bellia V, Peralta G, Alessi N, Migliara G. The combination of fenoterol and ipratropium bromide in bronchial asthma: Comparison of the acute effects of two different dosages. Respiration 1986;50(Suppl 2):148-51. [4488462]
28. Bourcereau J, Prosper M, Dy NR. Nebulized ipratropium bromide in the treatment of acute attacks of asthma and exacerbation of chronic bronchitis. European Respiratory Journal 1988;1:338s. [4488464]
29. Brenner M, Berkowitz R, Marshall N, Strunk RC. Need for theophylline in severe steroid-requiring asthmatics. Clinical Allergy 1998;18(2):143-50. [4488466]
30. Britton J, Hanley SP, Garrett HV, Hadfield JW, Tatterfield AE. Dose related effects of salbutamol and ipratropium bromide on airway calibre and reactivity in subjects with asthma. Thorax 1988;43:300-5. [4488468]
31. Bryant DH. Nebulized ipratropium bromide in the treatment of acute asthma. Chest 1985;88(1):24-9. [4488470]
32. Bryant DH, Rogers P. Oxitropium bromide: An acute dose response study of a new anticholinergic drug in combination with fenoterol in asthma and chronic bronchitis. Pulmonary Pharmacology 1990;3(2):55-8. [4488472]
33. Chen L, Deng K, Ye YQ. Effects of ipratropium bromide (IPB) and its combination with salbutamol sulfate (SAS) in acute asthmatic attack. Zhonghua Nei Ke Za Zhi [Chinese Journal of Internal Medicine] 1989;28(11):657-60. [4488474]
34. Chhabra SK, Pandey KK. Comparison of acute bronchodilator effects of inhaled ipratropium bromide and salbutamol in bronchial asthma. Journal of Asthma 2002;39(5):375-81. [4488476]
35. Cydulka RK, Emerman CL. Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of asthma. Annals of Emergency Medicine 1994;23(2):270-4. [4488478]
36. Garcia G, Bergna M, Nannini L, Neffen H, Rodrigo G, Mercurio S. Acute asthma in Buenos Aires. European Respiratory Journal 2012;40(56):1010. [4488480]
37. Gaur SN, Singh A, Kumar R. Evaluating role of inhaled magnesium sulphate as an adjunct to salbutamol and ipratropium in severe acute asthma. Chest 2008;134(4):91003. [4488482]
38. Gilman MJ, Meyer L, Carter J, Slovis C. Comparison of aerosolized glycopyrrolate and metaproterenol in acute asthma. Chest 1990;98(5):1095-8. [4488484]
39. Higgins RM, Stradling JR, Lane DJ. Should ipratropium bromide be added to beta-agonists in treatment of acute severe asthma?. Chest 1988;94(4):718-22. [4488486]
40. Hunt D, MacDonald GF, Reilly P, Plumley D, Kazim F. Bronchodilator response to several doses of ipratropium bromide in asthmatics and bronchitis. Current Therapeutic Research, Clinical and Experimental 1983;33(4):651-8. [4488488]
41. Janson C, Herala M, Sjögren I. Nebulization versus injection in ambulatory treatment of acute asthma: A comparative study. British Journal of Diseases of the Chest 1988;82(4):347-51. [4488490]
42. Kaik VG, Kaik B, Laggner A. Clinical pharmacological trials of a new metered dose inhaler, IK-6, a combination of the bronchodilators fenoterol and ipratropium bromide. Wiener Medizinische Wochenschrift 1980;130(11):385-93. [4488492]
43. Karpel JP, Appel D, Breidbart D, Fusco MJ. A comparison of atropine sulfate and metaproterenol sulfate in the emergency treatment of asthma. American Review of Respiratory Diseases 1986;133(5):727-9. [4488494]
44. Kerstjens HAM, Disse B, Schröder-Babo W, Bantje TA, Gahlemann M, Sigmund R, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial. Journal of Allergy and Clinical Immunology 2011;128(2):308-14. [4488496]
45. Koumbourlis A, Mastropietro C. Continuous inhalation of ipratropium bromide for acute asthma refractory to ß2-agonist treatment. Journal of Pediatric Pharmacological and Therapeutics 2015;20(1):66-9. [4488498]
46. Lanes SF, Garrett JE, Wentworth CH, FitzGerald JM, Karpel JP. The effect of adding ipratropium bromide to salbutamol in the treatment of acute asthma: A pooled analysis of three trials. Chest 1998;114(2):365-72. [4488500]
47. Leahy BC, Gomm SA, Allen SC. Comparison of nebulized salbutamol with nebulized ipratropium bromide in acute asthma. British Journal of Diseases of the Chest 1983;77(2):159-63. [4488502]
48. Lin RY, Pesola GR, Bakalchuk L, Heyl GT, Dow AM, Tenenbaum C, et al. Rapid improvement of peak flow in asthmatic patients treated with parenteral methylprednisolone in the emergency department: A randomized controlled study. Annals of Emergency Medicine 1999;33(5):487-94. [4488504]
49. Lin RY, Pesola GR, Bakalchuk L, Curry A, Nelson M, Lee H, et al. The effect of early parenteral administration of corticosteroids in severe asthma: A study not employing concomitant ipratropium treatment. Internet Journal of Asthma, Allergy and Immunology 2004; Vol. 3, issue 1. [4488506; URL: http://ispub.com/IJAAI/3/1/4365]
50. Louw SJ, Goldin JG, Isaacs S. Relative efficacy of nebulized ipratropium bromide and fenoterol in acute severe asthma. South African Medical Journal 1990;77(1):24-6. [4488508]
51. Maesen FP, Greefhorst LP, Smeets JJ, Wald FD, Cornelissen PJ. Therapeutic equivalence of a novel HFA134a-containing metered-dose inhaler and the conventional CFC inhaler (berodual) for the delivery of a fixed combination of fenoterol/ipratropium bromide. A randomized double-blind placebo-controlled crossover study in patients with asthma. Respiration 1997;64(4):273-80. [4488510]
52. Mazzei JA, Torres J. Blind randomized cross-over comparative study of salbutamol and the combination fenoterol-ipratropium IK6 in patients with bronchial asthma. Respiration 1986;50(Suppl 2):313-7. [4488512]
53. Nana A. Combination of nebulized ipratropium bromide and beta-agonists in the treatment of acute severe asthma. European Respiratory Journal 1995;8(Suppl 19):455s. [4488514]
54. Patrick DM, Dales RE, Stark RM, Laliberte G, Dickinson G. Severe exacerbations of COPD and asthma. Incremental benefit of adding ipratropium to usual therapy. Chest 1990;96(2):295-7. [4488516]
55. Rodrigo G, Rodrigo C, Burschtin O. A meta-analysis of the effects of ipratropium bromide in adults with acute asthma. American Journal of Medicine 1999;107(4):363-70. [4488518]
56. Roeseler J, Reynaert MS. A comparison of fenoterol and fenoterol-ipratropium nebulisation treatment in acute asthma. Acta Therapeutica 1987;13(6):571-8. [4488520]
57. Salome CM, Wright W, Sedgwick CJ, Woolcock AJ. Acute effects of fenoterol (Berotec) and ipratropium bromide (Atrovent) alone and in combination on bronchial hyper-responsiveness in asthmatic subjects. Progress in Clinical and Biological Research 1988;263:405-19. [4488522]
58. Schlueter DP, Neumann JL. Double blind comparison of acute bronchial and ventilation-perfusion changes to atrovent and isoproterenol. Chest 1978;73(6):982-3. [4488524]
59. Schneider J, Matsuda K, House SL, Ferguson I, Aubuchon K, Lewis L. Dyspnea scores may be a better predictor of hospital admissions than FEV1 for patients with acute asthma exacerbations. Academic Emergency Medicine. 2012; Vol. 19:S312. [4488526]
60. Stoodley RG, Aaron SD, Dales RE. The role of ipratropium bromide in the emergency management of acute asthma exacerbation: A meta analysis of randomized clinical trials. Annals of Emergency Medicine 1999;34(1):8-18. [4488528]
61. Tamura T, Chung T, Kabaroff A, Liss K, Villa-Roel C, Rowe BH. Pre-hospital management of patients with history of asthma and COPD in one Canadian urban setting. Canadian Journal of Emergency Medicine 2014;15(Suppl 1):S75. [4488530]
62. Toda M, Fukuda T, Motojima S, Makino S. Effect of the combination of fenoterol with oxitropium on asthmatic patients with acute air-way obstructions. European Respiratory Journal. 1992; Vol. 5:209s. [4488532]
63. Vogt R, Rychel F. Acute test comparing ipratropium bromide (SCH 1000), fenoterol, and placebo, by measured dose aerosol, in obstructive lung disease [Akuter vergleich von Sch 1000-, berotec- und placebo-dosieraerosol bei obstruktiven lungenerkrankungen]. Therapiewoche 1974;24(39):4228-34. [4488534]
64. Ward MJ, Fentem PH, Roderick Smith WH, Davies D. Ipratropium bromide in acute asthma. British Medical Journal 1981;282(6264):598-600. [4488536]
65. Youngchaiyud P, Charoenratanakul S, Suthamsmai T, Sriwatanakul K. Comparison of fenoterol, ipratropium bromide and their combination in asthma. Siriraj Hospital Gazette 1989;41(4):197-201. [4488538]
66. Zaritsky A, Qureshi F. Ipratropium does indeed reduce admissions to hospital with severe asthma. British Medical Journal 1999;318(7185):738. [4488540]
67. Aaron SD. The use of ipratropium bromide for the management of acute asthma exacerbation in adults and children: A systematic review. Journal of Asthma 2001;38(7):521-30.
68. Adams RJ, Fuhlbriggie A, Guilbert T, Lozano P, Martinez F. Inadequate use of asthma medication in the United States: Results of the Asthma in America national population survey. Journal of Allergy and Clinical Immunology 2002;110(1):58-64.
69. Braman SS. The global burden of asthma. Chest 2006;130(1 Suppl):4S-12S.
70. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2016. www.ginaasthma.org.
71. Grade Working Group. Grading quality of evidence and strength of recommendations. British Medical Journal 2004;328(7454):1490.
72. McMaster University. GRADEpro [www.gradepro.org]. Version [3.6]. McMaster University, 2014.
73. Grifths B, Ducharme FM. Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD000060.pub2]
74. Hasegawa K, Chiba T, Hagiwara Y, Watase H, Tsugawa Y, Brown DFM, et al. Japanese Emergency Medicine Network Investigators. Quality of care for acute asthma in emergency departments in Japan: A multicenter observational study. Journal of Allergy and Clinical Immunology: In Practice 2013;1(5):509-15.
75. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1. The Cochrane Collaboration 2011:Available from www.cochrane-handbook.org.
76. Krahn MD, Berka C, Langlois P, Detsky AS. Direct and indirect costs of asthma in Canada. Canadian Medical Association Journal 1996;154(6):821-31.
77. Lai CKW, de Guia TS, Kim YY, Kuo SH, Mukhopadhyay A, Soriano JB, et al. Asthma Insights and Reality in Asia-Pacific Steering Committee. Asthma control in the Asia-Pacific region: The Asthma Insights and reality in Asia-Pacific study. Journal of Allergy and Clinical Immunology 2003;111(2):263-8.
78. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Open Medicine 2009;3:123-9.
79. Morris JF, Koski A, Temple WP, Claremont A, Thomas DR. Fifteen year interval spirometric evaluation of the Oregon pedictive equations. Chest 1988;92:123-27.
80. Neffen H, Fritscher C, Schacht FC, Levy G, Chiarella P, Soriano JB, et al. Asthma control in Latin America: the Asthma Insights and Reality in Latin America (AIRLA) survey. Revista Panamericana de Salud Publica 2005;17(3):191-7.
81. Price AH, Clissold SP. Salbutamol in the 1980s. A reappraisal of its clinical efficacy. Drugs 1989;38(1):77-122.
82. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. European Respiratory Journal 2000;16(5):802-7.
83. Rashid MM, Khair MM, Hossain MA, Hassan MR. Newer effective treatment for adult patients with acute asthma with a multi-dose regimen of ipratropium bromide plus salbutamol using a spacer device in emergency department. Respirology 2012;17(Suppl 2):2.
84. The Cochrane Collaboration. Review Manager (RevMan) Version 5.3. Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration, 2014.
85. Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treatment of children and adults with acute asthma: A systematic review with meta-analysis. Thorax 2005;60(9):740-6.
86. Rowe BH, Bretzlaff JA, Bourdon C, Bota GW, Camargo CA. Intravenous magnesium sulfate treatment for acute asthma in the emergency department: A systematic review of the literature. Annals of Emergency Medicine 2000;36(3):181-90.
87. Rowe BH, Bretzlaff J, Bourdon C, Bota G, Blitz S, Camargo Jr CA. Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Cochrane Database of Systematic Reviews 2000, Issue 1. Art. No.: CD001490. [DOI: 10.1002/14651858.CD001490]
88. Rowe BH, Villa-Roel C, Abu-Laban RB, Stenstrom R, Mackey D, Stiell IG, et al. Admissions to Canadian hospitals for acute asthma: A prospective, multicentre study. Canadian Respiratory Journal 2010;17(1):25-30.
89. Santanello NC, Zhang J, Seidenberg B, Reiss TF, Barber BL. What are the minimal important changes for asthma measures in a clinical trial?. European Respiratory Journal 1999;14(1):23-7.
90. Smith DH, Malone DC, Lawson KA, Okamoto LJ, Battista C, Saunders WB. A national estimate of the economic costs of asthma. American Journal of Respiratory and Critical Care Medicine 1997;156(3 Pt 1):787-93.
91. Spooner C, Spooner GR, Jones AP, Rowe BH. Inhaled beta2-agonist and anticholinergic agents for emergency management of asthma in adults. Cochrane Database of Systematic Reviews 1998, Issue 4. [DOI: 10.1002/14651858.CD001284]